We are live on ! Find out more
IMUX icon

Immunic

40 hedge funds and large institutions have $102M invested in Immunic in 2014 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 2

350% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 4

101% more capital invested

Capital invested by funds: $50.9M → $102M (+$51.2M)

38% more funds holding

Funds holding: 2940 (+11)

Holders
40
Holders Change
+11
Holders Change %
+37.93%
% of All Funds
1.07%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
18
Reduced
4
Closed
2
Calls
Puts
Net Calls
Net Calls Change

IMUX Hedge Fund Activity: Q4 2014 in Review

40 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q4 2014, worth a combined $102M — up 101% from $50.9M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new IMUX positions and 2 closed out — a net gain of 11 holders — while 18 added to existing stakes and 4 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $9.63M. The largest seller was Goldman Sachs, cutting an estimated $547K.

  • 40 institutional investors held Immunic (IMUX) as of Q4 2014, up from 29 in Q3 2014.
  • Funds reported $102M of Immunic stock for Q4 2014, up 101% quarter-over-quarter.
  • 13 funds opened new Immunic positions in Q4 2014 and 2 closed out, a net change of +11 holders.
  • The largest Immunic buyer in Q4 2014 was Fidelity Investments, an estimated $9.63M added.
  • The largest Immunic seller in Q4 2014 was Goldman Sachs, an estimated $547K sold.

Based on aggregated 13F filings for Q4 2014.